ASCO 2023 | Age-stratified findings from the monarchE trial of abemaciclib in breast cancer

Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN, comments on results by age in the Phase III monarchE trial (NCT03155997) of adjuvant abemaciclib combined with endocrine therapy in patients with high-risk early breast cancer. Patients aged 65 years or over had survival outcomes similar to those who are younger. Safety and tolerability were also comparable, and dose reduction is additionally possible, reducing the rate of discontinuation. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.